Twin Cities-Based SynerFuse, Inc. Announces Management Team
The management team is as follows:
Justin Zenanko (Chief Executive Officer) is a Certified Public Accountant with extensive experience in corporate finance and startup development. He helped raise over $68 million with the Board and Management team of Recombinetics over the past 7 years. His positions at Recombinetics included CFO and SVP of Corporate Development; Zenanko now serves as a Director on the board of Recombinetics.
Dr. Susan Alpert (Chief Regulatory Officer) is a healthcare industry executive with a unique background that includes regulatory, clinical, business and technology experience. She previously served as Senior Vice President of Global Regulatory Affairs at Medtronic Inc., and as the Director of the Office of Device Evaluation at the FDA Center for Devices and Radiological Health. She serves on the boards of numerous professional organizations.
Dr. Gregory Molnar (Chief Scientific Officer) has over 20 years of experience as a medical device innovator. He was previously the Director of Neuromodulation Research at Medtronic Inc., and currently serves as a professor of neurology at the University of Minnesota. Dr. Molnar has authored numerous patents and publications in the neuromodulation space, and his research and inventions benefit patients today.
Beth Lindborg (Vice President Operations) has a technical/business hybrid background. She facilitates effective communication across all levels of medically-based organizations. Ms. Lindborg previously served as Director of Research and Marketing at BRTI Life Sciences.
“Justin is recruiting and securing the best possible team to develop and commercialize our game-changing device,” said Dr. Nazmi Peyman, Founder and Chief Medical Officer for SynerFuse. “The future is bright for our modulation-based pain management solution, and this is good news for patients, surgeons, payers and alike.”
SynerFuse is a Delaware corporation based in Minnesota—the heart of Medical Alley. The Company believes that individuals with chronic back pain and their providers deserve a better option than spinal fusion alone. Even when spinal fusion is successful, it can often result in residual chronic pain and use of addictive opioids.
The Company is creating a new future of superior, non-narcotic pain management with a patented therapy that integrates spinal fusion hardware, an active neuromodulation system, and sensors in a novel “smart” device which offers simplicity and efficiency during implantation.
Jordan Reyes, 845-781-3905